Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Lifeline Scientific (LSI)

  Print      Mail a friend

Monday 27 February, 2012

Lifeline Scientific

Machine Preservation 3 Year Study

RNS Number : 1355Y
Lifeline Scientific, Inc
27 February 2012

27 February 2012


 Lifeline Scientific, Inc

("Lifeline" or "the Company")


Machine preservation significantly improves kidney transplant survival over three years


New England Journal of Medicine publishes update on landmark Machine Preservation Trial


Lifeline Scientific, the medical technology company, announces the publication of three year follow-up data in the New England Journal of Medicine on the landmark Machine Preservation Trial1. The Machine Preservation Trial was the first large, randomised, prospective trial to compare the preservation of kidneys for transplant via LifePort® Kidney Transporter (marketed through the Company's Organ Recovery Systems division) with the traditional box of ice (static cold storage).




·     Overall, the benefits in graft survival seen at 1 year2 with LifePort machine perfusion persist after 3 years compared to traditional cold storage methods


·     The results show that three year graft survival is significantly greater in all transplanted kidneys machine perfused in the LifePort® Kidney Transporter compared static cold storage (91% vs. 87%, p=0.04)


·     The graft survival difference at three years was most pronounced for kidneys from expanded criteria donors* (86% vs. 76%, p=0.01)


·     Significantly, the results show that three year graft survival after machine perfusion compared to static cold storage was significantly superior for kidneys donated after brain death (91% vs. 86%, p=0.02)


·     Machine-perfused kidneys with delayed graft function (DGF) ‑ a delay in the recovery of renal function that requires dialysis within the first week after transplantation3 ‑ had better three year graft survival (77%) than cold stored kidneys with DGF (62%)


*Expanded criteria donors (ECDs), are those over the age of 60 or those over 50 with health conditions such as high blood pressure, stroke or poor kidney function. Over the last decade, kidney donations from ECDs have increased considerably and today comprise nearly half of the deceased donor kidneys transplanted in the US and EU.4,5


David Kravitz, Chief Executive of Lifeline, said: "The results of this follow-up study are very encouraging.  Because DGF cannot be predicted with certainty at the time of organ donation, and it is an established fact that a significant number of deceased donor kidney transplants experience DGF, the 3-year data demonstrates that, versus the traditional box of ice, LifePort machine perfusion is the best preservation modality from a patient outcomes perspective as it significantly improves the odds that a transplanted kidney will not experience DGF or fail within three years post transplant. Moreover, the trial demonstrated that results are all the more favorable for transplanted kidneys from expanded criteria donors."


Lead author Cyril Moers, MD PhD, University Medical Center Groningen, The Netherlands, said: "It is very interesting to see that the benefits in graft survival seen in this landmark study at 1 year with machine perfusion persist after 3 years compared to traditional cold storage methods. Since a growing number of organs available for transplantation come from older donors or from people with more complex medical conditions, it is particularly welcome that machine perfusion offers significant improvements for 3-year graft survival in kidneys from these donors and is a real step forward in kidney transplantation."


About the trial

·     The Machine Preservation Trial was a landmark, investigator-driven study, run by an independent scientific steering committee across the Netherlands, Belgium and the German federal state of North Rhine Westphalia, in collaboration with the Deutsche Stiftung Organtransplantation and Eurotransplant International Foundation (the international organ exchange organisation for Austria, Belgium, Croatia, Germany, Luxembourg, The Netherlands and Slovenia) as the central trial assistance desk. Principal investigators were Rutger Ploeg (Oxford, United Kingdom and Groningen, The Netherlands), Andreas Paul (Essen, Germany) and Jacques Pirenne (Leuven, Belgium).

·     The study was the first large randomised, prospective trial to compare machine perfusion with traditional cold static storage.

·     Three-year follow-up data were collected on all 672 recipients of consecutive kidneys donated after brain death or after cardiocirculatory death in the main data set, as well as 164 recipients of kidneys donated after cardiocirculatory death in the extended data set. One kidney from each of the 336 pairs included was randomly assigned to machine perfusion, and the contralateral organ to cold storage.

·     Earlier 12 month results from the Machine Preservation Trial, also published in the New England Journal of Medicine, showed that in transplanted kidneys preserved and transported in the LifePort Kidney Transporter, the odds of experiencing a delay in recovery of kidney function were 43% lower, and that these kidneys were 48% less likely to fail within a year compared to those stored in the traditional box of ice.


About the LifePort Kidney Transporter

LifePort is a proprietary medical device that preserves a donated kidney before it is transplanted. Designed to provide a sealed and sterile environment from the time of recovery until transplantation, LifePort gently pumps a specifically formulated solution through the kidney. This is referred to as 'machine perfusion' and is an important contrast to the traditional method of storing and transporting donated kidneys - packed in a box of ice (static cold storage).


About Lifeline Scientific Inc. 

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with European regional offices in Brussels, and South American regional offices in Sao Paulo.  The Company's focus is the global commercialisation of products to improve the preservation of organs for transplantation with its lead product, the FDA cleared, and CE marked, and clinically validated LifePort Kidney Transporter. Devices for preservation of the liver, pancreas, heart, and lung are in late stage pre-clinical development.


For further information please contact:


Lifeline Scientific, Inc.

+1 847-294-0300

David Kravitz, CEO

Seymour Pierce

+44 (0)20 7107 8000

Sarah  Jacobs / Mark Percy (Corporate Finance)

David Banks (Corporate Broking)

FTI Consulting

+44 (0)20 7831 3113

Simon Conway / John Dineen


1Moers C, Pirenne J, Paul, A, Ploeg RJ. Machine perfusion or cold storage in deceased-donor kidney transplantation. N.Eng J Med 2012;366:770-1.

2Moers C, Smits JM, Maathuis, MJ et al. Machine perfusion or cold storage in deceased-donor kidney transplantation .N Engl J Med 2009;360:7-19.

3Johnston TD, Thacker LR, Jeon H et al. Sensitivity of expanded-criteria donor kidneys to cold ischaemia time. Clin Trans 2004;18:28-32

4Eurotransplant data provided on request.

5OPTN. Available at

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t